Product Information
ARIXTRA is an innovative and effectivealternative anticoagulant
ARIXTRA is indicated for the prophylaxis
of deep vein thrombosis in:
- hip fracture surgery
- extended prophylaxis in hip fracture surgery
- knee replacement surgery
- hip replacement surgery
- Now approved for abdominal surgery in patients
at risk for thromboembolic complications
ARIXTRA is the first in a new class of anticoagulants
that offers convenient once-daily dosing for the treatment of:
- acute deep vein thrombosis (DVT) when
administered in conjunction with warfarin sodium
- acute pulmonary embolism (PE) when
administered in conjunction with warfarin sodium
when initial therapy is administered in the hospital
Arixtra, an injectable solution for subcutaneous use, has been approved as a preventative treatment for deep vein thrombosis (DVT) in adults undergoing hip fracture, hip replacement, or knee replacement surgery. It is adminstered through a single dose, prefilled syringe, affixed with an automatic needle protection system. Arixtra is the only antithrombotic agent approved in the United States for hip fracture surgery.
DVT is caused by a blood clot forming in a deep vein in the leg. It may cause pain and swelling, and enlargement and discoloration of the veins. The clot can grow in size and block other veins. Most seriously, portions of the clot may break away and travel through the veins to the lungs, leading to a life threatening pulmonary embolism.
Arixtra Side Effects:
Adverse events associated with the use of Arixtra may include (but are not limited to) the following:
Bleeding complications
Mild irritation at injection site
Anemia
Fever
Nausea
Edema
Constipation
Arixtra is used to reduce the risk of blood clots in the deep veins of the legs and thighs. These clots may break off and travel to the lungs (pulmonary embolism). Patients at risk for these complications include those undergoing:
hip fracture surgery,
hip replacement surgery,
knee replacement surgery,
abdominal surgery who are already at risk of blood clot complications
Arixtra also is used with warfarin to treat:
blood clots in the veins
blood clots that have broken off and traveled to the lungs (pulmonary embolism) when the patient is first treated in the hospital
Arixtra should not be given to patients who:
have severe kidney problems
weigh less than 110 pounds (50kg)
have bleeding anywhere
have a heart infection (bacterial endocarditis)
have a history of Arixtra causing the blood to have low platelets (thrombocytopenia)
are allergic to Arixtra or to any of the ingredients in Arixtra
Tell your healthcare provider if you have any of these conditions.
Arixtra, like other medicines that prevent the blood from clotting, is given with extreme caution to people who have conditions that have an increased risk of bleeding, such as:
bleeding disorders
ulcerative colitis and other bleeding disorders in the stomach and intestines
bleeding into the brain (hemorrhagic stroke)
recent brain, spinal, or eye surgery
taking other medicines that prevent the blood from clotting
